Company: ADPT
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030913
Chunk: 245

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-03-03
Form: 10-K
Item: Item 8
Chunk 245
---
    )

    (29,291
    )

    (56,496
    )

    Other

    27

    (73
    )

    169

    Net cash used in operating activities

    (95,212
    )

    (156,324
    )

    (183,945
    )

    Investing activities

    Purchases of property and equipment

    (3,664
    )

    (10,697
    )

    (16,349
    )

    Purchases of marketable securities

    (244,257
    )

    (429,558
    )

    (278,778
    )

    Proceeds from maturities of marketable securities

    325,713

    569,902

    298,032

    Net cash provided by investing activities

    77,792

    129,647

    2,905

    Financing activities

    Proceeds from exercise of stock options

    241

    2,245

    7,890

    Proceeds from revenue interest purchase agreement, net of issuance costs

    —

    —

    124,375

    Net cash provided by financing activities

    241

    2,245

    132,265

    Net decrease in cash, cash equivalents and restricted cash

    (17,179
    )

    (24,432
    )

    (48,775
    )

    Cash, cash equivalents and restricted cash at beginning of year

    67,996

    92,428

    141,203

    Cash, cash equivalents and restricted cash at end of year
     
    $
    50,817

    $
    67,996

    $
    92,428

    Noncash investing activities

    Purchases of equipment included in accounts payable and accrued liabilities
     
    $
    1,275

    $
    687

    $
    1,719

    Supplemental disclosure of cash flow information

    Cash paid for interest
     
    $
    8,864

    $
    8,985

    $
    494

The accompanying notes are an integral part of these consolidated financial statements.

95

Adaptive Biotechnologies Corporation